CN107771078B - 用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 - Google Patents
用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 Download PDFInfo
- Publication number
- CN107771078B CN107771078B CN201680025775.1A CN201680025775A CN107771078B CN 107771078 B CN107771078 B CN 107771078B CN 201680025775 A CN201680025775 A CN 201680025775A CN 107771078 B CN107771078 B CN 107771078B
- Authority
- CN
- China
- Prior art keywords
- methyl
- yloxy
- cancer
- methoxyquinolin
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 36
- 150000003839 salts Chemical class 0.000 title abstract description 36
- 238000002360 preparation method Methods 0.000 title description 16
- 239000002246 antineoplastic agent Substances 0.000 title description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 claims 5
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 238000010189 synthetic method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- -1 RT: room temperature Chemical compound 0.000 description 18
- 238000000634 powder X-ray diffraction Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 208000014829 head and neck neoplasm Diseases 0.000 description 14
- 239000012458 free base Substances 0.000 description 13
- 150000003890 succinate salts Chemical class 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 10
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 10
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 10
- 229960001592 paclitaxel Drugs 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 206010014733 Endometrial cancer Diseases 0.000 description 8
- 208000034578 Multiple myelomas Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 206010005003 Bladder cancer Diseases 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 206010038389 Renal cancer Diseases 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 7
- 206010017758 gastric cancer Diseases 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- 201000010982 kidney cancer Diseases 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 208000026037 malignant tumor of neck Diseases 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 201000011549 stomach cancer Diseases 0.000 description 7
- 201000002510 thyroid cancer Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 201000005112 urinary bladder cancer Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 229940123237 Taxane Drugs 0.000 description 6
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 230000001875 tumorinhibitory effect Effects 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- UMWRMOYYUHIPDT-UHFFFAOYSA-N 4-fluoro-2-methyl-1h-indol-5-ol Chemical compound OC1=CC=C2NC(C)=CC2=C1F UMWRMOYYUHIPDT-UHFFFAOYSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004137 elotuzumab Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UEBYQHIBYHJDLX-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine hydrate dihydrochloride Chemical compound O.Cl.Cl.FC1=C2C=C(NC2=CC=C1OC1=CC=NC2=CC(=C(C=C12)OC)OCC1(CC1)N)C UEBYQHIBYHJDLX-UHFFFAOYSA-N 0.000 description 1
- UUAKQNIPIXQZFN-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine;dihydrochloride Chemical compound Cl.Cl.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 UUAKQNIPIXQZFN-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- MGURPNCXRLKQAR-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-ol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=C3C=C(C(=CC3=NC=C2)O)OC)=C1 MGURPNCXRLKQAR-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- VKOQTKCUAXALQO-SPIKMXEPSA-N C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.FC1=C2C=C(NC2=CC=C1OC1=CC=NC2=CC(=C(C=C12)OC)OCC1(CC1)N)C Chemical compound C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.FC1=C2C=C(NC2=CC=C1OC1=CC=NC2=CC(=C(C=C12)OC)OCC1(CC1)N)C VKOQTKCUAXALQO-SPIKMXEPSA-N 0.000 description 1
- DPFCMSHHKYDCFU-UHFFFAOYSA-N C1(CC1)NC(OCOC1=C(C=C2C(=CC=NC2=C1)OC=1C(=C2C=C(NC2=CC=1)C)F)OC)=O Chemical compound C1(CC1)NC(OCOC1=C(C=C2C(=CC=NC2=C1)OC=1C(=C2C=C(NC2=CC=1)C)F)OC)=O DPFCMSHHKYDCFU-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 238000011199 Dunnett post hoc test Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- VAZQQRNYILEOGE-UHFFFAOYSA-N benzyl n-[1-(hydroxymethyl)cyclopropyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(CO)CC1 VAZQQRNYILEOGE-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- SXPYUZHVBRBIGO-UHFFFAOYSA-N butanedioic acid 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound OC(=O)CCC(O)=O.COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1 SXPYUZHVBRBIGO-UHFFFAOYSA-N 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111453058.8A CN114129567A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452231.9A CN110292580B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910543920.0A CN110172057B (zh) | 2015-05-04 | 2016-05-03 | 喹啉衍生物的盐及其结晶形式 |
CN201910451534.9A CN110294741B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202310823755.0A CN116898849A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452221.5A CN110292579B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202111450705.XA CN114099510A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562156734P | 2015-05-04 | 2015-05-04 | |
US62/156,734 | 2015-05-04 | ||
US201562205272P | 2015-08-14 | 2015-08-14 | |
US62/205,272 | 2015-08-14 | ||
US15/143,630 | 2016-05-02 | ||
US15/143,630 US9751859B2 (en) | 2015-05-04 | 2016-05-02 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
PCT/US2016/030483 WO2016179123A1 (en) | 2015-05-04 | 2016-05-03 | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910543920.0A Division CN110172057B (zh) | 2015-05-04 | 2016-05-03 | 喹啉衍生物的盐及其结晶形式 |
CN202310823755.0A Division CN116898849A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452231.9A Division CN110292580B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910451534.9A Division CN110294741B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202111453058.8A Division CN114129567A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452221.5A Division CN110292579B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202111450705.XA Division CN114099510A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107771078A CN107771078A (zh) | 2018-03-06 |
CN107771078B true CN107771078B (zh) | 2021-11-02 |
Family
ID=57218545
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680025775.1A Active CN107771078B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 |
CN201910452221.5A Active CN110292579B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452231.9A Active CN110292580B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202310823755.0A Pending CN116898849A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202111450705.XA Pending CN114099510A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910543920.0A Active CN110172057B (zh) | 2015-05-04 | 2016-05-03 | 喹啉衍生物的盐及其结晶形式 |
CN202111453058.8A Pending CN114129567A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910451534.9A Active CN110294741B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910452221.5A Active CN110292579B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910452231.9A Active CN110292580B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202310823755.0A Pending CN116898849A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN202111450705.XA Pending CN114099510A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910543920.0A Active CN110172057B (zh) | 2015-05-04 | 2016-05-03 | 喹啉衍生物的盐及其结晶形式 |
CN202111453058.8A Pending CN114129567A (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
CN201910451534.9A Active CN110294741B (zh) | 2015-05-04 | 2016-05-03 | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US9751859B2 (zh) |
EP (1) | EP3291814A4 (zh) |
JP (2) | JP2018515482A (zh) |
KR (1) | KR102613409B1 (zh) |
CN (8) | CN107771078B (zh) |
AU (2) | AU2016257816A1 (zh) |
CA (1) | CA2984444A1 (zh) |
EA (1) | EA201792355A1 (zh) |
MX (1) | MX2017014108A (zh) |
TW (1) | TWI704142B (zh) |
WO (1) | WO2016179123A1 (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
AU2015290007B2 (en) | 2014-07-14 | 2019-11-21 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as pi3k, mTor inhibitors |
AU2015360095B2 (en) | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
CN108601773A (zh) | 2015-07-11 | 2018-09-28 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的稠合喹啉化合物 |
CN107296811B (zh) * | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
CN108778336A (zh) | 2016-12-01 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂与parp抑制剂联合在制备治疗胃癌的药物中的用途 |
WO2018214925A1 (zh) * | 2017-05-26 | 2018-11-29 | 正大天晴药业集团股份有限公司 | 用于治疗结直肠癌的喹啉衍生物 |
CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
CA3080644A1 (en) | 2017-12-06 | 2019-06-13 | Quanren WANG | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer |
CN107970241B (zh) * | 2018-01-22 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用 |
CN114716410A (zh) * | 2018-02-11 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
EP3766870B1 (en) | 2018-03-02 | 2023-09-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof |
CN110357856B (zh) * | 2018-04-09 | 2021-02-26 | 新发药业有限公司 | 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法 |
CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
CN112368273A (zh) * | 2018-06-25 | 2021-02-12 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的晶习及其结晶粉末的制备方法 |
KR20210034613A (ko) * | 2018-07-18 | 2021-03-30 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 퀴놀린 유도체 및 항체의 약물 조합 |
CN108864050B (zh) * | 2018-07-25 | 2019-12-10 | 上海博璞诺科技发展有限公司 | 一种合成安罗替尼及其盐酸盐的方法 |
EP3854396A4 (en) * | 2018-09-18 | 2022-06-29 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative used for treating small cell lung cancer |
CN112638385B (zh) * | 2018-09-18 | 2023-03-31 | 正大天晴药业集团股份有限公司 | 用于治疗脑肿瘤的喹啉衍生物 |
CN109748904A (zh) * | 2019-01-31 | 2019-05-14 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
WO2020181214A1 (en) * | 2019-03-07 | 2020-09-10 | Advenchen Pharmaceuticals, LLC | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment |
CA3137204A1 (en) * | 2019-04-19 | 2020-10-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma |
CN113747898A (zh) * | 2019-05-10 | 2021-12-03 | 正大天晴药业集团股份有限公司 | 用于联合治疗软组织肉瘤的喹啉衍生物 |
EP3973964A4 (en) * | 2019-05-20 | 2023-05-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER |
EP3973963A4 (en) * | 2019-05-23 | 2023-06-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | QUINOLINE DERIVATIVES FOR THE TREATMENT OF HEAD AND NECK CANCER |
CN113939315B (zh) * | 2019-05-30 | 2024-04-02 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗黑色素瘤的联用药物组合物 |
US20220378776A1 (en) * | 2019-11-04 | 2022-12-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Drug combination of quinoline derivative and pd-1 monoclonal antibody |
EP4091613A4 (en) * | 2020-01-19 | 2024-02-21 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | QUINOLINE DERIVATIVE FOR TREATING RHEUMATOID ARTHRITIS |
CN113262223A (zh) * | 2020-02-17 | 2021-08-17 | 上海交通大学医学院 | 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用 |
WO2022033585A1 (zh) * | 2020-08-13 | 2022-02-17 | 正大天晴药业集团股份有限公司 | 用于治疗软组织肉瘤的联用药物 |
CN113116896A (zh) * | 2021-04-30 | 2021-07-16 | 厦门大学附属第一医院 | 安罗替尼在制备急性髓系白血病干细胞杀伤药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EP2129379B1 (en) | 2007-02-20 | 2019-04-10 | Novartis AG | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
RU2011119478A (ru) * | 2008-10-14 | 2012-11-27 | Нин Си | Соединения и способы применения |
IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
CN103664892B (zh) * | 2010-08-01 | 2015-09-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
CN103664890B (zh) * | 2010-08-01 | 2016-10-05 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶及制备方法 |
CA2855950C (en) | 2011-11-14 | 2017-05-09 | Centaurus Biopharma Co., Ltd. | Kinase modulating compounds, compositions containing the same and use thereof |
WO2014032019A2 (en) * | 2012-08-23 | 2014-02-27 | Georgetown University | Compounds and methods of use thereof for treating tumors |
MX2015008543A (es) | 2013-01-18 | 2015-11-16 | Advenchen Pharmaceuticals Llc | Proceso para preparar el agente antitumoral 6-(7-((1-aminoaciclopr opil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y su cristalino. |
CN105189462B (zh) * | 2013-02-20 | 2017-11-10 | 卡拉制药公司 | 治疗性化合物和其用途 |
CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
AU2015290007B2 (en) | 2014-07-14 | 2019-11-21 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as pi3k, mTor inhibitors |
AU2015360095B2 (en) | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
CN108601773A (zh) | 2015-07-11 | 2018-09-28 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的稠合喹啉化合物 |
CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
-
2016
- 2016-05-02 US US15/143,630 patent/US9751859B2/en active Active
- 2016-05-03 AU AU2016257816A patent/AU2016257816A1/en not_active Abandoned
- 2016-05-03 CN CN201680025775.1A patent/CN107771078B/zh active Active
- 2016-05-03 CN CN201910452221.5A patent/CN110292579B/zh active Active
- 2016-05-03 CN CN201910452231.9A patent/CN110292580B/zh active Active
- 2016-05-03 EP EP16789916.0A patent/EP3291814A4/en active Pending
- 2016-05-03 MX MX2017014108A patent/MX2017014108A/es unknown
- 2016-05-03 EA EA201792355A patent/EA201792355A1/ru unknown
- 2016-05-03 CN CN202310823755.0A patent/CN116898849A/zh active Pending
- 2016-05-03 WO PCT/US2016/030483 patent/WO2016179123A1/en active Application Filing
- 2016-05-03 JP JP2017557130A patent/JP2018515482A/ja not_active Abandoned
- 2016-05-03 CN CN202111450705.XA patent/CN114099510A/zh active Pending
- 2016-05-03 CN CN201910543920.0A patent/CN110172057B/zh active Active
- 2016-05-03 CN CN202111453058.8A patent/CN114129567A/zh active Pending
- 2016-05-03 KR KR1020177034805A patent/KR102613409B1/ko active IP Right Grant
- 2016-05-03 CN CN201910451534.9A patent/CN110294741B/zh active Active
- 2016-05-03 CA CA2984444A patent/CA2984444A1/en active Pending
- 2016-05-04 TW TW105113816A patent/TWI704142B/zh active
-
2017
- 2017-07-25 US US15/659,510 patent/US10100034B2/en active Active
-
2018
- 2018-09-07 US US16/125,401 patent/US10544125B2/en active Active
-
2020
- 2020-11-30 AU AU2020281003A patent/AU2020281003B2/en active Active
-
2021
- 2021-03-01 JP JP2021031318A patent/JP7195551B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107771078B (zh) | 用于制备抗癌剂1-((4-(4-氟-2-甲基-1h-吲哚-5-基氧基)-6-甲氧基喹啉-7-基氧基)甲基)环丙胺、其结晶形式和其盐的方法 | |
JP6703075B2 (ja) | Rhoキナーゼ阻害剤 | |
JP6431593B6 (ja) | ピリジニルアミノピリミジン誘導体、その製造方法、および用途 | |
EA011237B1 (ru) | 4-фениламинохиназолин-6-ил-амиды | |
ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
MX2010012692A (es) | Derivados de quinazolina. | |
CN106905316A (zh) | 蛋白激酶抑制剂 | |
JP2016515997A (ja) | 重水素化フェニルアミノピリミジン化合物およびこの化合物を含む薬物組成物 | |
CN110857292A (zh) | 一种egfr激酶抑制剂及其制备方法和应用 | |
CN116199685A (zh) | Her2降解剂及其用途 | |
CN101611011A (zh) | 化合物 | |
EA040599B1 (ru) | Применение кристаллической формы 1-((4-(4-фтор-2-метил-1h-индол-5-илокси)-6-метоксихинолин-7-илокси)метил)циклопропанамина или его соли в комбинированной терапии для лечения рака | |
CN111065635B (zh) | 作为mth1抑制剂的新型嘧啶衍生物 | |
CN114787145B (zh) | 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物 | |
BR112017023639B1 (pt) | Forma cristalina de 1-((4-(4-fluoro-2-metil1h-indol-5-iloxi)-6-metoxi- quinolin-7- iloxi)metil)ciclopropanamina e forma cristalina de um sal de 1-((4-(4- fluoro-2-metil-1h-indol-5-iloxi)-6-metoxi-quinolin-7-iloxi)metil)ciclopropanamina | |
KR20170068170A (ko) | 유방암 치료를 위한 피라지노인돌론 유도체 약학적 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180322 Address after: Hangzhou City, Zhejiang province Yuhang District No. 1500 West Street warehouse before 6 Branch Center Building 5 unit 1101 East Block Applicant after: ADVENCHEN PHARMACEUTICALS LLC Applicant after: Advenchen Laboratories, LLC Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: The United States of California Parke Moore Applicant before: Edward Medicine Co., Ltd. Applicant before: National Day Paul Chen |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1250923 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |